Aptevo Therapeutics Inc. (APVO): R&D Expense
$14.54M
Year ended 2025-12-31
$15.20M
Trailing 12 months to 2026-06-30
-6.7%
3-year compound annual growth
-4.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.54M | +1.1% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $14.38M | -16.0% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $17.11M | -4.3% | 2025-02-14, From 2023-01-01 |
| 2022-12-31 | $17.88M | -5.9% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $18.99M | +6.4% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $17.85M | -27.9% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $24.76M | n/c | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $35.38M | +21.9% | 2020-03-25, From 2018-01-01 |
| 2017-12-31 | $29.02M | -0.3% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $29.12M | n/c | 2018-03-13, From 2016-01-01 |
| 2015-12-31 | $34.73M | n/a | 2017-03-31, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $14.54M | +1.1% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $20.53M | +54.0% |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $42.36M | +126.5% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $4.39M | +66.0% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $24.90M | -26.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
Compare APVO, HURA, SKYE, BYSI side by side · Screen every company in Pharmaceutical Preparations ↗